Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 86, Issue 7, Pages 625-627Publisher
WILEY-BLACKWELL
DOI: 10.1002/ajh.22041
Keywords
-
Categories
Funding
- NCI NIH HHS [K23 CA118419] Funding Source: Medline
Ask authors/readers for more resources
We retrospectively analyzed clinical outcomes of patients aged 18-59 with cytogenetically normal acute myeloid leukemia (CN-AML) and mutations in the FLT3 receptor according to type of postremission therapy. Specifically, we compared the outcomes of patients who underwent autologous SCT versus consolidation chemotherapy. There were 37 patients with an ITD mutation (seven also had a TKD mutation) and 19 patients with an isolated TKD mutation at diagnosis. In all, patients with an isolated TKD (n = 16) had an improved disease free survival (DFS) and overall survival (OS) (P = 0.031 and 0.014, respectively) compared to ITD patients (n = 21). For individuals with an isolated TKD mutation, survival outcomes were similar irrespective of the type of postremission therapy (n = 7 for SCT and 9 for chemotherapy; P = 0.97 and 0.082, respectively). However, ITD positive patients who underwent an autologous SCT in CR1 (n = 10) had an improved DFS but similar OS compared to those who received consolidation chemotherapy (n = 11; P = 0.05 and 0.27). These results suggest that high-dose chemotherapy with autologous SCT may be a reasonable therapeutic choice over consolidation chemotherapy for young CN-AML patients with a FLT3ITD mutation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available